Multicenter, prospective, non-selection study to evaluate Endometrial Receptivity Analysis in patients with previous implantation failures.
ERA Non-Selection
The study
Embryo implantation is a key step on pregnancy establishment, and the optimal period for this to happen is a very tight time frame, known as window of implantation (WOI), when the endometrium is most receptive. While general menstrual cycle phases have been classically assessed by histology evaluation, the Endometrium Receptivity Analysis (ERA®) developed by Igenomix sets the moment of endometrium receptivity in an accurate and non-subjective way. The ERA® test analyzes a group of genes related to endometrial receptivity, therefore allowing for a personalization of an embryo transfer at a more reliable time for a successful implantation.
Igenomix R&D is currently conducting a study to improve the diagnosis of the endometrial receptivity in an infertile population with previous implantation failures. For this, we will evaluate the impact of this diagnosis on the reproductive outcomes of a deferred embryo transfer.
The study population will consist of infertile women (18 to 37 years old) with a scheduled IVF treatment who have had previous failed transfer/s of genetically tested/non-tested embryos.
The scientific team
This study, coordinated by Diana Valbuena MD, PhD and Maria Ruiz MSc, has been approved by the Comité de Bioética en Investigación de Pacífica Salud Hospital Punta Pacífica and will be carried out by Dr. Roberto Epifanio at The Fertile Group. If you are interested in getting any further details, please contact Dr. Roberto Epifanio at The Fertile Group, Panamá, https://www.fertileg.com , (+507) 3821400, recepcion@fertileg.com. The researchers at the center will provide you with as much information as you need without any commitment and will assess whether you meet the necessary requirements to participate.
If you are eligible and you finally wish to participate, you should know that your participation in the study will not entail any additional expenses beyond the standard costs of your planned reproductive treatments at your clinic. Igenomix will cover the expenses of a single PGT-A analysis (test for embryo genetic anomalies) and many of the expenses related with the hormone treatment needed for sample collection (hormone replacement medication and analytics, ERA® test, etc.).
Your participation would comprise an estimated total time of 18 months, corresponding to 1 month for the stimulation cycle and PGT-A, 1-2 months for endometrial preparation and samples collection, 1-2 months for the transfer and up to 13 months to follow-up the possible pregnancy outcomes.
Roberto Epifanio, MD
Data protection
Lastly, we remind you that, if you take part of the selection process, your personal data may be recorded by the clinic with the only purpose of contacting you. These data will be treated in accordance with the provisions of the local data protection legislation in force.
